The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
Open accessAbstract
Histone deacetylase inhibitors (HDACi) developed as anti-cancer agents have a high degree of selectivity for killing cancer cells. HDACi induce acetylation of histones and nonhistone proteins, which affect gene expression, cell cycle progression, cell migration, and cell death. The mechanism of the tumor selective action of HDACi is unclear. Here, we show that the HDACi, vorinostat (Suberoylanilide hydroxamic acid, SAHA), induces DNA double-strand breaks (DSBs) in normal (HFS) and cancer (LNCaP, A549) cells. Normal cells in contrast to cancer cells repair the DSBs despite continued culture with vorinostat. In transformed cells, phosphorylated H2AX (γH2AX), a marker of DNA DSBs, levels increased with continued culture with vorinostat, whereas in normal cells, this marker decreased with time. Vorinostat induced the accumulation of acetylated histones within 30 min, which could alter chromatin structure-exposing DNA to damage. After a 24-h culture of cells with vorinostat, and reculture without the HDACi, γH2AX was undetectable by 2 h in normal cells, while persisting in transformed cells for the duration of culture. Further, we found that vorinostat suppressed DNA DSB repair proteins, e.g., RAD50, MRE11, in cancer but not normal cells. Thus, the HDACi, vorinostat, induces DNA damage which normal but not cancer cells can repair. This DNA damage is associated with cancer cell death. These findings can explain, in part, the selectivity of vorinostat in causing cancer cell death at concentrations that cause little or no normal cell death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chen, C.-S., Wang, Y.-C., Yang, H.-C., Huang, P.-H., Kulp, S. K., Yang, C.-C., Lu, Y.-S., Matsuyama, S., Chen, C.-Y., & Chen, C.-S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3996 · Cited by 187
RetractedLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Twenty-Five Years of the Nucleosome, Fundamental Particle of the Eukaryote Chromosome
Kornberg, R. D., & Lorch, Y. (1999) · Cell · doi:10.1016/s0092-8674(00)81958-3 · Cited by 1,830
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584
Marks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,196
Self-citationStucki, M., Clapperton, J. A., Mohammad, D., Yaffe, M. B., Smerdon, S. J., & Jackson, S. P. (2005) · Cell · doi:10.1016/j.cell.2005.09.038 · Cited by 1,099
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Self-citationChemical phylogenetics of histone deacetylases
Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.313 · Cited by 720
Histone deacetylase inhibitors: Potential in cancer therapy
Marks, P. A., & Xu, W. ‐. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22185 · Cited by 712
Self-citationTherapeutic application of histone deacetylase inhibitors for central nervous system disorders
Kazantsev, A. G., & Thompson, L. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2681 · Cited by 711
Signatures of mutation and selection in the cancer genome
Bignell, G. R., Greenman, C. D., Davies, H., Butler, A. P., Edkins, S., Andrews, J. M., Buck, G., Chen, L., Beare, D., Latimer, C., et al. (2010) · Nature · doi:10.1038/nature08768 · Cited by 707
DNA Repair in Mammalian Cells: Base excision repair: the long and short of it
Robertson, A. B., Klungland, A., Rognes, T., & Leiros, I. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-8736-z · Cited by 651
Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon‐Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2000) · PubMed · Cited by 615
Self-citationInhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.
Kim, M. S., Blake, M., Baek, J. H., Kohlhagen, G., Pommier, Y. G., & Carrier, F. (2003) · PubMed · Cited by 529
Ungerstedt, J. S., Sowa, Y., Xu, W.-S., Shao, Y., Dokmanovic, M., Perez, G., Ngo, L., Holmgren, A., Jiang, X., & Marks, P. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408732102 · Cited by 503
Self-citationRuefli, A. A., Ausserlechner, M. J., Bernhard, D., Sutton, V. R., Tainton, K. M., Kofler, R., Smyth, M. J., & Johnstone, R. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191208598 · Cited by 488
Characteristics of γ-H2AX foci at DNA double-strand breaks sites
Pilch, D. R., Sedelnikova, O. A., Redon, C., Celeste, A., Nussenzweig, A., & Bonner, W. M. (2003) · Biochemistry and Cell Biology · doi:10.1139/o03-042 · Cited by 451
Munshi, A., Kurland, J. F., Nishikawa, T., Tanaka, T., Hobbs, M. L., Tucker, S. L., Ismail, S., Stevens, C., & Meyn, R. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2088 · Cited by 345
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
Duvic, M., & Vu, J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.7.1111 · Cited by 344
Kelly, W. K., & Marks, P. A. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0106 · Cited by 330
Self-citationHDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation
Parmigiani, R. B., Xu, W. S., Venta-Perez, G., Erdjument-Bromage, H., Yaneva, M., Tempst, P., & Marks, P. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803749105 · Cited by 321
Self-citationDNA Repair in Mammalian Cells: DNA double-strand break repair: how to fix a broken relationship
Pardo, B., Gómez-González, B., & Aguilera, A. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-8740-3 · Cited by 280
Histone Deacetylase Inhibitors: Current Status and Overview of Recent Clinical Trials
Ma, X., Ezzeldin, H. H., & Diasio, R. B. (2009) · Drugs · doi:10.2165/11315680-000000000-00000 · Cited by 227
Enhancing the apoptotic and therapeutic effects of HDAC inhibitors
Frew, A. J., Johnstone, R. W., & Bolden, J. E. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.042 · Cited by 219
Rational Combinations Using HDAC Inhibitors
Bots, M., & Johnstone, R. W. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2786 · Cited by 217
HDAC inhibitors as anti‐inflammatory agents
Adcock, I. M. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707166 · Cited by 216
Ramalingam, S. S., Parise, R. A., Ramananthan, R. K., Lagattuta, T. F., Musguire, L. A., Stoller, R. G., Potter, D. M., Argiris, A. E., Zwiebel, J. A., Egorin, M. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0162 · Cited by 193
Development of vorinostat: Current applications and future perspectives for cancer therapy
Richon, V. M., Garcia-Vargas, J., & Hardwick, J. S. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.002 · Cited by 169
Epigenetic Modifiers: Basic Understanding and Clinical Development
Piekarz, R., & Bates, S. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2788 · Cited by 151
Histone deacetylase inhibitors: insights into mechanisms of lethality
Rosato, R. R., & Grant, S. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.4.809 · Cited by 139
Selective Growth Inhibition of Tumor Cells by a Novel Histone Deacetylase Inhibitor, NVP-LAQ824
Atadja, P. W., Gao, L., Kwon, P. O., Trogani, N., Walker, H., Hsu, M., Yeleswarapu, L., Chandramouli, N., Perez, L. B., Versace, R. W., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2043 · Cited by 133
Histone deacetylase inhibitors and genomic instability
Éot-Houllier, G., Fulcrand, G., Magnaghi-Jaulin, L., & Jaulin, C. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.06.005 · Cited by 132
Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate
Qiu, L., Kelso, M. J., Hansen, C. P., West, M. L., Fairlie, D. P., & Parsons, P. G. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690493 · Cited by 115
Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer
Botrugno, O. A., Santoro, F., & Minucci, S. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.027 · Cited by 114
Vorinostat in cutaneous T-cell lymphoma
Duvic, M. A., & Vu, J. (2007) · Drugs of today · doi:10.1358/dot.2007.43.9.1112980 · Cited by 76
Shiozawa, K., Nakanishi, T., Tan, M., Fang, H.-B., Wang, W.-C., Edelman, M. J., Carlton, D., Gojo, I., Sausville, E. A., & Ross, D. D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1587 · Cited by 64
Reversible acetylation of non histone proteins: role in cellular function and disease.
Batta, K., Das, C., Gadad, S. S., Shandilya, J., & Kundu, T. K. (2007) · PubMed · Cited by 55
Kano, Y., Akutsu, M., Tsunoda, S., Izumi, T., Kobayashi, H., Mano, H., & Furukawa, Y. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-9000-0 · Cited by 48
Reversible Acetylation Of Non Histone Proteins: Role in cellular function and disease
Batta, K., Das, C., Gadad, S. S., Shandilya, J., & Kundu, T. K. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/1-4020-5466-1_9 · Cited by 46
Bishton, M. J., Kenealy, M. K., Johnstone, R. W., Rasheed, W. K., & Prince, H. M. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.10.1439 · Cited by 45
Histone deacetylase inhibitors: A new perspective for the treatment of leukemia
Abujamra, A. L., dos Santos, M. P., Roesler, R., Schwartsmann, G., & Brunetto, A. L. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.08.021 · Cited by 26
DNA methylation: A promising target for the twenty-first century
Abreu, P. A., Dellamora-Ortiz, G. M., Leão-Ferreira, L. R., Gouveia, M., Braggio, E., Zalcberg, I. R., Santos, D. O., Bourguinhon, S., Cabral, L. M., Rodrigues, C. R., et al. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.8.1035 · Cited by 13
Cited by
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
Archin, N. M., Liberty, A. L., Kashuba, A. D., Choudhary, S. K., Kuruc, J. D., Crooks, A. M., Parker, D. C., Anderson, E. M., Kearney, M. F., Strain, M. C., et al. (2012) · Nature · doi:10.1038/nature11286 · Cited by 1,139
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Mottamal, M., Zheng, S., Huang, T., & Wang, G. (2015) · Molecules · doi:10.3390/molecules20033898 · Cited by 680
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
Bose, P., Dai, Y., & Grant, S. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.04.004 · Cited by 280
Histone Deacetylase 6 and Heat Shock Protein 90 Control the Functions of Foxp3 + T-Regulatory Cells
de Zoeten, E. F., Wang, L., Butler, K., Beier, U. H., Akimova, T., Sai, H., Bradner, J. E., Mazitschek, R., Kozikowski, A. P., Matthias, P., et al. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05155-11 · Cited by 258
Metadata
- Authors
- Lee, J.-H., Choy, M. L., Ngo, L., Foster, S. S., & Marks, P. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2010-08-02
- Volume
- 107
- Issue
- 33
- Pages
- 14639-14644
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2146320180
- Cited by
- 363
- References
- 44
- FWCI
- 10.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.